Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00112554 · ClinicalTrials.gov registry record · Phase 3
Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia
A Phase 3 study, sponsored by Vion Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 420
- Enrollment target
NCT00112554 is a Phase 3 study that has completed, run by Vion Pharmaceuticals. The registered enrollment target is 420 participants.
The verdict
NCT00112554, a Phase 3 study, has completed, sponsored by Vion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 420 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as cytarabine and VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This randomized phase III trial is studying cytarabine and VNP40101M to see how well they work compared to cytarabine alone in treating patients with relapsed acute myeloid leukemia.
Interventions
- OTHER placebo
- DRUG cytarabine
- DRUG laromustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2005-03 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00112554
The ClinicalTrials.gov registry entry for NCT00112554 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vion Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00112554 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00112554 about?
NCT00112554 is a clinical study titled "Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia". RATIONALE: Drugs used in chemotherapy, such as cytarabine and VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This randomize...
What is the current status of trial NCT00112554?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 420 participants. The study started on 2005-03. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00112554?
The interventions under investigation include: placebo (OTHER), cytarabine (DRUG), laromustine (DRUG).
Who is sponsoring clinical trial NCT00112554?
This trial is sponsored by Vion Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.